| Literature DB >> 25995334 |
Margaret Corrigan1, Gideon M Hirschfield2, Ye H Oo1, David H Adams1.
Abstract
INTRODUCTION: Autoimmune hepatitis is a chronic immune-mediated liver injury, frequently associated with progression to end-stage liver disease if untreated. Patients commonly present with hepatitis, positive immune serology, elevated immunoglobulins and compatible liver histology, in the absence of an alternative aetiology. SOURCES OF DATA: Data for this review were obtained using PubMed. AREAS OF AGREEMENT: Disease usually responds to steroids and azathioprine, and appears to be a manifestation of autoimmune predisposition triggered in genetically susceptible individuals exposed to likely environmental challenges. We provide an up-to-date approach to disease understanding and management along with the clinical approach to diagnosis and current treatment suggestions. AREAS OF CONTROVERSY: Controversies such as second line therapies and novel markers of disease activity are introduced. GROWING POINTS: Increased understanding of the immunoregulatory mechanisms behind autoimmune hepatitis has led to opportunities for new therapies. These are developed including a discussion of timely research studies relevant to future therapies for patients.Entities:
Keywords: autoimmune liver disease; azathioprine; immune mediated liver disease; prednisolone
Mesh:
Substances:
Year: 2015 PMID: 25995334 DOI: 10.1093/bmb/ldv021
Source DB: PubMed Journal: Br Med Bull ISSN: 0007-1420 Impact factor: 4.291